Image Ben Hargreaves Oncology The gut microbiome: the next breakthrough in cancer? Ben Hargreaves discovers how research has emerged outlining how the gut microbiome plays a crucial role in patients’ response to cancer treatments. Market Access Capping the cost of insulin: altruistic or strategic? The rising price of insulin has become one of the most talked about issues across the pharma industry. Market Access Are we entering a new era of blockbuster weight-loss drugs? As revenues fall in diabetes treatments, has the industry found a new revenue driver in weight-loss treatments? R&D Allogeneic therapies: The future of cancer treatment? As autologous cancer therapies have advanced and shown incredible efficacy, the industry is looking for the next step for this type of treatment. Load more results
Oncology The gut microbiome: the next breakthrough in cancer? Ben Hargreaves discovers how research has emerged outlining how the gut microbiome plays a crucial role in patients’ response to cancer treatments.
Market Access Capping the cost of insulin: altruistic or strategic? The rising price of insulin has become one of the most talked about issues across the pharma industry.
Market Access Are we entering a new era of blockbuster weight-loss drugs? As revenues fall in diabetes treatments, has the industry found a new revenue driver in weight-loss treatments?
R&D Allogeneic therapies: The future of cancer treatment? As autologous cancer therapies have advanced and shown incredible efficacy, the industry is looking for the next step for this type of treatment.
News Clinical trial go-between Inato raises $20m Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t
R&D Sponsored Trials and tribulations of drug development What does it take to establish new treatments for rare diseases?
